Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Tumor heterogeneity in 18F-FDG PET/CT as a biomarker for prediction of treatment response and locoregional recurrence in patients with pharyngeal cancer treated with chemoradiotherapy

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

YOUNG MI Seol

Citation

Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527

Authors

Y.M. Seol1, J.Y. Jang2, K. Park3, Y.J. Choi4

Author affiliations

  • 1 Hematology-oncology, Pusan National University Hospital, 602-739 - Busan/KR
  • 2 Otorhinolaryngology-head And Neck Surgery, Pusan National University Hospital, Busan/KR
  • 3 Nuclear Medicine, Pusan National University Hospital, Busan/KR
  • 4 Hematology-oncology, Pusan National University Hospital, Busan/KR
More

Resources

Abstract 944

Aim/Background

This study aimed to explore the predictive value of intratumoral heterogeneity of 18F-FDG uptake in pharyngeal cancer treated with chemoradiotherapy.

Methods

These analyses included 52 consecutive patients with pharyngeal cancer who underwent 18F-FDG PET/CT before definitive chemoradiotherapy. The heterogeneity factor (HF) was defined as the derivative (dV/dT) of a volume-threshold function for a primary tumor and metastatic lymph nodes, respectively. The relationships between clinical parameters and HF in primary tumor (pHF) and metastatic lymph nodes (nHF) were analyzed.

Results

The HF ranged from -1.367 to -0.027 (median -0.152) in primary tumor. The pHF was significantly correlated with SUVmax, metabolic tumor volume, total lesion glycolysis. Response to induction chemotherapy was not correlated with pHF while response to radiotherapy was significantly better in patients with high pHF (low heterogeneity). Consistently, the 2-year locoregional recurrence-free survival was significantly better in patients with high pHF (82.9% in -0.152 < pHF versus 30.5% in -0.152 > pHF, log-rank p = 0.009). However, nHF (ranged from -1.067 to -0.039 (median -0.160)) was not significantly correlated with response to radiotherapy and locoregional recurrences.

Conclusions

The pHF was a significant predictive value of radiation response and locoregional recurrence in pharyngeal cancer while nHF was not a significant predictive factor.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings